In this issue of Bone Marrow Transplantation, El-Jawahri and colleagues studied 1 medically fit persons, 60-75 years of age, with myelodysplastic syndrome (MDS) willing to be considered for a reduced-intensity conditioning transplant. They found no significant association between patient-reported quality-of-life and likelihood of proceeding to a transplant. Although this finding surprised the authors, there are several reasons this outcome could be predicted. We discuss why in the commentary which follows.
First, as the authors note, their conclusion applies only to persons who made it to the Dana-Farber Cancer Institute (DFCI) or Massachusetts General Hospital (MGH) to be evaluated. Most subjects in their study came from New England (median distance to their centres was 115 km), so getting there was not a major issue. However, Boston is 2050 km from Plato, Missouri, the mean population centre of the US based on 2010 census data. Also, New Englanders are not average Americans. For example, Plato is the birthplace of screenwriter Josh Senter; he is known for his work on 'Desperate Housewives'. We doubt many New Englanders have seen 'Desperate Housewives', certainly not the authors of this study. ('Desperate Clinicians' perhaps?). On the other hand, not many people in Plato know where Sweden is. Our point is conclusions of this study should be viewed in a regional context and not assumed to apply nationally. People living elsewhere or travelling longer distances to a transplant centre such as Memorial Sloan Kettering in New York (which is, for the uninformed, definitely not part of New England) or the Fred Hutchinson Centre in Seattle may have different outcomes than those in this study. Ironically, Plato is only 900 km to MD Anderson where Professor Richard Champlin would surely have persuaded a higher proportion of people to have a transplant. More on this below.
Another issue is why subjects went to these transplant centres and not other centres. As it happens, there are few transplant centres in New England, so this is probably not a big issue. Some subjects may have been self-referred, for example, after googling on the web. (Yes, it is a word according to the Oxford English Dictionary). (Google comes from the word googol, which means 10 100 . Larry Page and Sergey Brin did not know the proper spelling of the word so they have used Google to illustrate the huge quantity of available, but not searchable data.) Others may have been attracted by the excellence of these centres while still others may have been referred by family members, their physician(s) or both. Several of these factors may operate in some or even in most cases. The authors considered many variables in their analyses of associations with the likelihood of receiving a reduced-intensity conditioning allotransplant including age, gender (we think they mean sex), cytogenetics, Eastern Cooperative Oncology Group (ECOG) performance score, International Prognostic Scoring System (IPSS) score and distance from the centre.
Baseline patient-reported quality-of-life was ascertained with the EORTC QLQ-C30 instrument previously validated in several cancers. However, as the authors note, sensitivity and specificity of this instrument in MDS are unknown. Although measures of patient-reported quality-of-life are associated with transplant outcomes in some studies, this is an entirely different question than whether these measures are associated with likelihood of receiving a transplant. And although physicians were not informed of the results of the EORTC QLQ-C30 questionnaire, they were allowed to question subjects and form their opinion of a subject's quality-of-life. Unfortunately, these queries were neither scripted nor results systematically recorded nor analysed. Although neither physician-assigned ECOG performance score nor patient-reported quality-of-life was significantly associated with likelihood of receiving a transplant, it would be interesting to know if these variables correlated.
There are several important messages from this study. One is that only about one-third of subjects received a transplant. This is a bit surprising, but we do not know what proportion of subjects went to these centres for a transplant evaluation versus a MDS evaluation. The authors say the subjects were willing to be considered for a reduced-intensity conditioning transplant, but this neither tells us why they went to these centres nor how many persons wanted a different type of transplant, perhaps a conventional transplant, and so went elsewhere after their Boston evaluation. The authors think this possibility unlikely because their subjects are not so well informed about their disease and therapy options. We cannot, of course, comment on their subjects, but many persons with MDS are quite well-informed on these issues.
Patients and physicians often have different perceptions of why they agree to a therapy evaluation. Some patients are interested in recommendations arising from the evaluation, whereas others may have been pressured by a family member against their will to consider a therapy option. And perhaps a few 60-65-year-olds had heard of results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901 trial of reduced-intensity conditioning in MDS and AML closed before complete accrual, because of inferior outcomes in the reduced-intensity conditioning arm. 2 If they went for a transplant evaluation, why did they not proceed to a transplant, and are they entitled to a gas or air ticket rebate? (Gas cost much more than $1.89/gallon when the study was done, and a Kayak search yesterday has a round-trip airfare of $1240.) Nicely, DFCI gives gas cards for return clinic visits. But who would not give someone a $50 gas card to get a $1500 return visit or a $100 000 transplant? Smart businessmen.
As the authors note, the only variables significantly associated with likelihood of receiving a transplant were younger age, highrisk cytogenetics and higher IPSS score. The latter were co-linear, so two models were explored; IPSS score seemed the stronger. Results of these analyses are not surprising given prior studies of variables associated with transplant outcomes in MDS and the Markov modelling of optimal timing of transplants by several of the authors. 3, 4 The authors started with the hypothesis that compromised patient-reported quality-of-life at enrollment would be an important factor predicting the receipt of a reduced-intensity conditioning transplant. (As expert statisticians, we are certain they started instead with the null hypothesis.) Why? The issue of quality-of-life is complex, even in otherwise well persons. How is your quality-of-life today after your son crashed your Lamborghini? For example, one can imagine someone with MDS and a poor disease-related quality-of-life opting for a transplant, but one can equally imagine them being afraid of a high risk of immediate death from a transplant, and declining or postponing a transplant until their quality-of-life improves, perhaps after non-transplant therapy(ies). It is difficult to predict which way the pendulum might swing in different persons or even the same person on different occasions. Fight with your wife over the childrens' allowances just before the doctor arrives: go for a transplant. Family brings the children for a visit or their college tuition bills arrive: hypo-methylating drugs. Or vice versa. And although the authors' focus was on disease-related quality-of-life rather than Lamborghini crashes, there is no guarantee this is how subjects understood the purpose of the questionnaire. Also, quality-of-life, even if disease-related, can vary considerably over time such that a static measurement or point estimate is not ideal.
Several potentially important variables were not considered by the authors. The first is whether a donor was available and, if yes, what type. Surely donor type strongly influences a person's decision whether to agree to proceed to a transplant and a physician's enthusiasm for recommending one by substantially changing the benefit-to-risk ratio. A proposed transplant from a genetically-identical twin looks a lot different than a transplant of HLA-mismatched umbilical cord blood cells, especially if you weigh 120 kg. Also, we are not told what proportion of subjects were known to have a donor before coming for an evaluation. Another possibility is some persons unknown to the authors had an unsuccessful donor search elsewhere and were not referred for an evaluation. This is unlikely for Caucasians, but could partially explain the lower than expected frequencies of African Americans and Asians in the study. (Finances are another explanation.)
A second unexplored issue is affordability/insurance coverage. For example, after adjusting for variables such as race and stage, men 465 years with early prostate cancer and private insurance are fourfold more likely to be treated by prostatectomy than men with Medicare insurance, 48 versus 12%. 5 In the context of MDS, most insurers will pay for drugs; transplants are another story. (This recently changed with Medicare approval that would apply to subjects 465 years in this study.) This variable may not operate for Massachusetts residents who have good governmental insurance coverage, but we are not told how many subjects were from other states with less generous insurance coverage (and lower taxes as a consequence).
A third potentially important variable is the impact of physician judgment and biases. Every physician knows one of the most important determinants of a person's choice between therapy options is how he/she (recently, 'they' has been suggested as a singular pronoun, a proposal we reject) presents the options and benefit-to-risk ratio. Physicians are reasonably good at estimating how someone will do with an intensive medical intervention. Precisely how they do this is unknown: call it clinical ability if you like, a term preferred by Professor Gianni Barosi. For example, in several studies of intensive therapy of AML physicians were routinely better at predicting therapy-related mortality than complex algorithms using diverse variables as measured by receiver-operator characteristic curves and C-statistics (E Estey, personal communication). This process is sometimes referred to as 'I know it when I see it', a phrase first used by United States Supreme Court Justice, Potter Stewart, in 1964 to describe his threshold test for obscenity in Jacobellis vs Ohio. In explaining why the material at issue was not obscene and therefore protected speech, he opined: 'I shall not today attempt further to define the kinds of material I understand to be embraced within that shorthand description (pornography) and perhaps I could never succeed in intelligibly doing so. But I know it when I see it'.
Many physicians enter therapy alternative discussions with biases. Some are transplanters (a concept we think is inappropriate) whereas others have an ecumenical view of MDS therapy seeing transplants as but one option. It is unclear if assignment to the physician presenting the therapy choice to subjects in this study was random, probably not, and whether this variable was adjusted for. Physicians have beliefs, some supported by data, many not. Usually, there is an inverse relationship between strength of data supporting a conclusion and strength of physicians' opinions. Heat is inversely related to light, namely, beliefs people hold with the greatest strength are often in areas where we lack definitive data. Reinhold Niebuhr said it best: 'Frantic orthodoxy is never rooted in faith but in doubt. It is when we are not sure that we are doubly sure'. Sometimes when physicians see a person with MDS, they judge to have a poor quality-of-life, they reason a transplant is needed. In other instances or with other physicians (or both), the thinking may be a poor quality-of-life is likely to be associated with a high likelihood of a poor outcome. Physicians may hesitate to recommend an intensive therapy such as a transplant in this circumstance. Nobody likes an iatrogenic death even though death from disease and death from therapy are scored identically in a Kaplan-Meier survival curve. Morally, ethically and emotionally these deaths are not equivalent. Too many iatrogenic deaths can ruin a physician's quality-of-life, discourage the nurses, prompt queries from hospital administration, ruin your centre's statistics and so on.
The authors state MDS is a complex disease and physician recommendations are the primary driver of most treatment decisions. True. Consider again therapy of prostate cancer. Most medical oncologists (with no skin in the game) agree outcomes of surgery and radiation therapy are comparable. How then do we explain Medicare claims data showing radiation therapy is used twice as often as surgery in Massachusetts, but in Oregon the converse is so. Simple. In Massachusetts, there is a strong radiation therapy programme at the Joint Centre for Radiation Therapy; urological surgery is weaker. The converse is so in Oregon. However, both states mandate physicians to present these therapy alternatives. Consequently, there must be something in how physicians present outcomes data to people that results in this extraordinary difference in prostatectomy versus radiation therapy rates between these states. Another issue is selective memory. Several studies indicate physicians' memory of outcomes of therapy interventions is disproportionally influenced by outcomes in the prior two to three persons they treated. In one study, heart surgeons were asked to estimate post-operative survival rates in their practices. These estimates were compared with Medicare data from these practices. Surgeons overestimated survival about twofold. This is easily understood. We recall patients we see in our office; few physicians make rounds at cemeteries. Biases also operate in reverse. For example, several studies indicate physicians systematically underestimate survival of persons with incurable cancers by a factor of fivefold.
6 Consider the convicted Lockerbie bomber with advanced prostate cancer, released from prison, because experts estimated his survival at o3 months, but he died 42 years later.
Is any of this important when we try to analyse why some people receive a therapy such as a transplant, whereas others, seemingly comparable, do not? Yes. Very. Most people do not realise a therapy they are likely to receive often reflects their physician's education, experiences, especially most recent experiences and other biases. (As Valjean says in Les Misérables: let us not speak of money.) (The strong influence of most recent experiences on memory is why restaurants put greater emphasis on extraordinary desserts than extraordinary appetisers.) In prostate cancer, these differences in therapy choices are not as serious as it seems because of similar outcomes of prostatectomy and radiation therapy. But can we say the same for alternative therapies of MDS? No. Moreover, what if the subjects had gone to the new MGH concierge medical service at 50 Staniford Street where physicians can apparently spend days or weeks chatting with you instead of 55 Fruit Street where you are more likely to get an hour or two?
There are also important implications of these issues to conclusions we can rightly draw using transplant-based observational databases such as those of the Centre for International Blood and Marrow Research (CIBMTR) and the European Bone Marrow Transplant Group (EBMT). These registries collect outcomes data from persons receiving a transplant. Persons medically fit to receive a transplant, but for certain reasons (reasons we discuss, reasons we do not discuss, and reasons unknown and/or by chance) did not, are excluded. The caveat is that conclusions from these valuable analyses from CIBMTR and EBMT may not apply to every medically fit person with the disease being considered. And yes, this includes the person you evaluate for a transplant in your clinic tomorrow.
Although it may appear we are trashing the typescript of El-Jawahri and colleagues, we think they have done a good job and applaud their efforts to determine why some medically fit persons with MDS receive a reduced-intensity conditioning transplant and others do not. We could not have done better. This question is, of course, entirely different than who, if anyone 60-75 years and medically fit, should receive a reduced-intensity allotransplant in Boston or anywhere else, and, if yes, when during the course of their disease. The authors have tried to answer this question in other reports. 3, 4 We agree with the authors that knowing how these decisions are made is more complex than can be determined from their study. Designing a study focused on how transplant decisions are made is probably more important than the sensitivity of the instrument(s) used. Take home message: caveat emptor until we figure this out, if ever.
